Outcomes of Drug-Coated Balloon Versus Drug-Eluting Stent for In-Stent Restenosis and De-Novo Lesions: A Meta-Analysis of Randomized Controlled Trials

Outcomes of Drug-Coated Balloon Versus Drug-Eluting Stent for In-Stent Restenosis and De-Novo Lesions: A Meta-Analysis of Randomized Controlled Trials Publisher

Moghadam AS ; Kazemian S ; Shojaei S ; Moghadam SS ; Dolama RH ; Ebrahimi R ; Shirmard FO ; Pourfaraji SMA ; Najafi MS ; Hobaby S ; Soleimani H ; Tajdini M ; Tehrani B ; Kolte D Show All Authors

Moghadam AS
Kazemian S
Shojaei S
Moghadam SS
Dolama RH
Ebrahimi R
Shirmard FO
Pourfaraji SMA
Najafi MS
Hobaby S
Soleimani H
Tajdini M
Tehrani B
Kolte D
Elgendy I
Basavarajaiah S
Latib A
Sattar Y
Chadi Alraies M
Hosseini K

Source: Health Science Reports Published:2026

Abstract

Background and Aims: Drug-coated balloons (DCBs) and drug-eluting stents (DESs) are commonly used in percutaneous coronary interventions (PCI), but their long-term comparative effectiveness remains unclear. This meta-analysis aimed to compare the clinical and angiographic outcomes of DCB versus DES in patients with in-stent restenosis (ISR) and de novo lesions, including ST-elevation myocardial infarction (STEMI) and small vessel disease (SVD). Methods: A systematic search identified randomized controlled trials (RCTs) comparing DCBs and DESs. The primary outcome was target lesion revascularization (TLR), with secondary outcomes including all-cause mortality, cardiovascular mortality, myocardial infarction, stent/lesion thrombosis, and late lumen loss (LLL). The frequentist network meta-analysis and binary random-effect analysis were used to compare DCB versus. DES. Results: A total of 21 RCTs with 4244 patients were included. In ISR patients, the risk of TLR was comparable between DCB vs. DES at 1-year (OR: 1.36, 95% CI: 0.86–2.14) and beyond 1-year (OR: 1.23, 95% CI: 0.79–1.93). DCB and DES showed no significant difference in other secondary outcomes at 1-year and beyond. In STEMI and SVD patients, DCB and DES demonstrated similar outcomes, except for a lower LLL after DCB in patients with SVD (SMD: −0.38, 95% CI: −0.53 to −0.22). Conclusion: DCB and DES were associated with a similar risk of TLR in patients with ISR, STEMI, and SVD. The results were consistent at 1-year and beyond time intervals. Furthermore, DCB was associated with a lower LLL compared to DES in patients with SVD. © 2026 The Author(s). Health Science Reports published by Wiley Periodicals LLC.

Related Docs

View other Related Docs

1. Dual Antiplatelet Therapy Duration and Stent Type in Patients With High Bleeding Risk: A Systematic Review and Network Meta-Analysis, American Heart Journal (2025)

2. Limus- Versus Paclitaxel-Coated Balloons for Coronary In-Stent Restenosis: Meta-Analysis of Randomized Controlled Trials, Cardiovascular Intervention and Therapeutics (2026)

3. Drug-Eluting Stent Versus Bare Metal Stent for Symptomatic Intracranial Stenosis: A Comparative Systematic Review and Meta-Analysis Study, European Journal of Clinical Pharmacology (2025)

Experts (# of related papers)

Kaveh Hosseini (1)

Farnaz Khatami (1)

Style	Citing Format
MLA	Moghadam AS, et al.. "Outcomes of Drug-Coated Balloon Versus Drug-Eluting Stent for In-Stent Restenosis and De-Novo Lesions: A Meta-Analysis of Randomized Controlled Trials." Health Science Reports, vol. 9, no. 5, 2026, pp. -.
APA	Moghadam AS, Kazemian S, Shojaei S, Moghadam SS, Dolama RH, Ebrahimi R, Shirmard FO, Pourfaraji SMA, Najafi MS, Hobaby S, Soleimani H, Tajdini M, Tehrani B, Kolte D, Elgendy I, Basavarajaiah S, Latib A, Sattar Y, Chadi Alraies M, Hosseini K (2026). Outcomes of Drug-Coated Balloon Versus Drug-Eluting Stent for In-Stent Restenosis and De-Novo Lesions: A Meta-Analysis of Randomized Controlled Trials. Health Science Reports, 9(5), -.
Chicago	Moghadam AS, Kazemian S, Shojaei S, Moghadam SS, Dolama RH, Ebrahimi R, Shirmard FO, et al.. "Outcomes of Drug-Coated Balloon Versus Drug-Eluting Stent for In-Stent Restenosis and De-Novo Lesions: A Meta-Analysis of Randomized Controlled Trials." Health Science Reports 9, no. 5 (2026): -.
Harvard	Moghadam AS et al. (2026) 'Outcomes of Drug-Coated Balloon Versus Drug-Eluting Stent for In-Stent Restenosis and De-Novo Lesions: A Meta-Analysis of Randomized Controlled Trials', Health Science Reports, 9(5), pp. -.
Vancouver	Moghadam AS, Kazemian S, Shojaei S, Moghadam SS, Dolama RH, Ebrahimi R, et al.. Outcomes of Drug-Coated Balloon Versus Drug-Eluting Stent for In-Stent Restenosis and De-Novo Lesions: A Meta-Analysis of Randomized Controlled Trials. Health Science Reports. 2026;9(5):-.
BibTex	@article{ author = {Moghadam AS and Kazemian S and Shojaei S and Moghadam SS and Dolama RH and Ebrahimi R and Shirmard FO and Pourfaraji SMA and Najafi MS and Hobaby S and Soleimani H and Tajdini M and Tehrani B and Kolte D and Elgendy I and Basavarajaiah S and Latib A and Sattar Y and Chadi Alraies M and Hosseini K}, title = {Outcomes of Drug-Coated Balloon Versus Drug-Eluting Stent for In-Stent Restenosis and De-Novo Lesions: A Meta-Analysis of Randomized Controlled Trials}, journal = {Health Science Reports}, volume = {9}, number = {5}, pages = {-}, year = {2026} }
RIS	TY - JOUR AU - Moghadam AS AU - Kazemian S AU - Shojaei S AU - Moghadam SS AU - Dolama RH AU - Ebrahimi R AU - Shirmard FO AU - Pourfaraji SMA AU - Najafi MS AU - Hobaby S AU - Soleimani H AU - Tajdini M AU - Tehrani B AU - Kolte D AU - Elgendy I AU - Basavarajaiah S AU - Latib A AU - Sattar Y AU - Chadi Alraies M AU - Hosseini K TI - Outcomes of Drug-Coated Balloon Versus Drug-Eluting Stent for In-Stent Restenosis and De-Novo Lesions: A Meta-Analysis of Randomized Controlled Trials JO - Health Science Reports VL - 9 IS - 5 SP - EP - PY - 2026 ER -

Science Communicator Platform

Authors

Abstract